Results 1-10 out of 106
-
Results of Placing and Open Offer
25 March 2008 -
Proposed Placing and Open Offer to raise £8.6 million
28 February 2008 -
Interim Management Statement for 3 months ended 31 December 2007
18 February 2008 -
$1.16 million funding for Cogane™
21 January 2008Phytopharm plc (LSE: PYM) (“Phytopharm” or the “Company”) announces today that it has been awarded funding by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support the development of Cogane™ as a treatment for Parkinson’s disease (PD).
-
Preliminary Results for the period ended 30 September 2007
29 November 2007 -
Phytopharm initiates Stage 3 activities of Joint Development Agreement for Hoodia extract with Unilever
24 September 2007GODMANCHESTER, Cambridgeshire, U.K. (24 September 2007) – Phytopharm plc (LSE: PYM) (”Phytopharm”) announces today that it continues to make good progress on its weight management product, Hoodia extract in collaboration with Unilever.
-
Successful completion of Phase Ib clinical study for Myogane™
30 July 2007GODMANCHESTER, Cambridgeshire, U.K. (30 July 2007) – Phytopharm plc (LSE: PYM) (“Phytopharm” or the “Company”) announces today that it has successfully completed a Phase Ib healthy volunteer clinical study for Myogane™.
-
Collaboration and Licence Agreement with The Beijing Institute for novel memory and concentration product
26 June 2007Phytopharm plc announces today a Collaboration and Licence Agreement with The Beijing Institute, Academy of Military Medical Sciences "The Beijing Institute") for the development of novel functional foods and pharmaceuticals, including a product for memory and concentration.
-
Appointment of Chairman
20 June 2007Phytopharm plc today announces the appointment of Alistair Taylor as Non-Executive Chairman. Mr Taylor will join the Board of Phytopharm plc with effect from 18 July, succeeding Dr Paul Whitney who retires from the Company after 10 years. This appointment completes the planned restructuring of the board.
-
Cogane™ data presented at ‘11th International Congress of Parkinson’s Disease and Movement Disorders’
05 June 2007GODMANCHESTER, Cambridgeshire, U.K. (5 June 2007) – Phytopharm plc (LSE: PYM) (“Phytopharm” or the “Company”) announces today pre-clinical data showing that Cogane™ reverses the changes in the area of the brain involved in Parkinson’s disease.